CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target
T Behl, I Kaur, L Aleya, A Sehgal, S Singh… - Science of the Total …, 2022 - Elsevier
The combat against the Corona virus disease of 2019 (COVID-19), has created a chaos
among the healthcare institutions and researchers, in turn accelerating the dire need to …
among the healthcare institutions and researchers, in turn accelerating the dire need to …
The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and …
DB Kell, E Pretorius - Biochemical Journal, 2022 - portlandpress.com
Ischaemia–reperfusion (I–R) injury, initiated via bursts of reactive oxygen species produced
during the reoxygenation phase following hypoxia, is well known in a variety of acute …
during the reoxygenation phase following hypoxia, is well known in a variety of acute …
Does evidence exist to blunt inflammatory response by nutraceutical supplementation during covid-19 pandemic? An overview of systematic reviews of vitamin d …
More than one year has passed since the first cases of coronavirus disease 2019 (COVID-
19) caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus were reported …
19) caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus were reported …
SARS-CoV-2 cell entry beyond the ACE2 receptor
SD Alipoor, M Mirsaeidi - Molecular biology reports, 2022 - Springer
Background Angiotensin-converting enzyme 2 (ACE2) is known as the major viral entry site
for SARS-CoV-2. However, viral tissue tropism and high rate of infectivity do not directly …
for SARS-CoV-2. However, viral tissue tropism and high rate of infectivity do not directly …
A mid-pandemic night's dream: Melatonin, from harbinger of anti-inflammation to mitochondrial savior in acute and long COVID-19
IG Lempesis, VE Georgakopoulou… - International …, 2024 - spandidos-publications.com
Coronavirus disease 2019 (COVID-19), a systemic illness caused by severe acute
respiratory distress syndrome 2 (SARS-CoV-2), has triggered a worldwide pandemic with …
respiratory distress syndrome 2 (SARS-CoV-2), has triggered a worldwide pandemic with …
Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality
The fear of SARS-CoV-2 infection is due to its high mortality related to seasonal flu. To date,
few medicines have been developed to significantly reduce the mortality of the severe …
few medicines have been developed to significantly reduce the mortality of the severe …
A deadly embrace: Hemagglutination mediated by SARS-CoV-2 spike protein at its 22 N-glycosylation sites, red blood cell surface sialoglycoproteins, and antibody
DE Scheim - International journal of molecular sciences, 2022 - mdpi.com
Rouleaux (stacked clumps) of red blood cells (RBCs) observed in the blood of COVID-19
patients in three studies call attention to the properties of several enveloped virus strains …
patients in three studies call attention to the properties of several enveloped virus strains …
Targeting host defense system and rescuing compromised mitochondria to increase tolerance against pathogens by melatonin may impact outcome of deadly virus …
DX Tan, R Hardeland - Molecules, 2020 - mdpi.com
Fighting infectious diseases, particularly viral infections, is a demanding task for human
health. Targeting the pathogens or targeting the host are different strategies, but with an …
health. Targeting the pathogens or targeting the host are different strategies, but with an …
The coronavirus disease 2019 (COVID-19): key emphasis on melatonin safety and therapeutic efficacy
Viral infections constitute a tectonic convulsion in the normophysiology of the hosts. The
current coronavirus disease 2019 (COVID-19) pandemic is not an exception, and therefore …
current coronavirus disease 2019 (COVID-19) pandemic is not an exception, and therefore …
Candidate psychotropics against SARS–CoV–2: A narrative review
M Khosravi - Pharmacopsychiatry, 2022 - thieme-connect.com
Since few therapeutic options are clinically accessible for coronavirus disease 2019 (COVID-
19), effective, safe, and globally available pharmaceuticals need to be urgently developed to …
19), effective, safe, and globally available pharmaceuticals need to be urgently developed to …